TISSIUM
74, Rue du Faubourg Saint-Antoine
Paris
75012
France
Tel: 33-1-76-21-72-28
Website: http://www.tissium.com/
31 articles with TISSIUM
-
BioSpace Movers & Shakers, March 26
3/26/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses.
-
TISSIUM Selected for French Tech 120 Program
2/9/2021
TISSIUM, a privately-owned medtech company developing biomorphic programmable polymers for tissue reconstruction, announced today it has been named a French Tech 120 company for the 2021 program.
-
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
-
BioSpace Movers & Shakers, Dec. 18
12/18/2020
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
TISSIUM Receives FDA Investigational Device Exemption for Vascular Sealant
11/17/2020
TISSIUM, a privately-owned medtech company developing biomorphic programmable polymers for tissue reconstruction, announced today it has received approval from the U.S. Food and Drug Administration for its Investigational Device Exemption application for its vascular sealant. The approval is the most recent validation of TISSIUM’s efforts to de
-
TISSIUM Secures €7M State Guaranteed Loan
10/1/2020
TISSIUM, a privately-owned medtech company developing biomorphic programmable polymers for tissue reconstruction, announced today it has secured a €7M state-guaranteed loan ( Prêt Garanti par l’Etat , or PGE). The loan was awarded by BNP Paribas, CM-CIC and bpifrance. Initiated by the French Government to support companies during the COVID-19 crisis, the PGE is a bank loan with a fixed interest rate ranging from 0.25% and 1.
-
TISSIUM Receives CE Mark and Announces Manufacturing Compliance Certification from TÜV SÜD
4/2/2020
TISSIUM, a privately-owned life science company developing fully synthetic, biomorphic programmable polymers, announced the receipt of a CE-mark for its sterile biodegradable sealant in a pre-filled syringe.
-
BioSpace Global Roundup, March 5
3/5/2020
Life sciences companies from across the globe provide updates on their businesses and pipelines. -
BioSpace Global Roundup, Feb. 13
2/13/2020
Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses. -
TISSIUM Receives Funding From the Crohn's & Colitis Foundation to Improve IBD Patient Outcomes
2/11/2020
Feb. 11, 2020 13:00 UTC PARIS--( BUSINESS WIRE )-- TISSIUM, a privately-owned life science company developing fully synthetic, biomorphic programmable polymers, announced today that they have received funding from the Crohn's & Colitis Foundation's IBD Ventures, a funding mechanism intended to accelerate the discovery and development of novel research-based products with the potential to alleviate suffering caused by inflammatory bowel disease (IBD). The funding will support T
-
BioSpace Global Roundup, Jan. 23
1/23/2020
Companies from across the globe provide updates on their businesses and pipelines. -
TISSIUM Recognized as a French Tech 120 Company
1/21/2020
TISSIUM, a privately-owned life science company developing fully synthetic, biomorphic programmable polymers, announced it has been named a French Tech 120 company.
-
BioSpace Global Roundup, Nov. 21
11/21/2019
Companies from across the globe provide updates on their businesses and pipelines. -
TISSIUM Closes €39M Series B Funding Round
11/20/2019
TISSIUM, a privately-owned life science company developing fully synthetic, biomorphic programmable polymers, announced it has raised €38.75 million in a Series B round of funding.
-
TISSIUM Announces Publication in The Journal of Cardiovascular Surgery Detailing Preclinical and Clinical Evaluation of SETALIUMTM Vascular Sealant
5/16/2019
SETALIUMTM Vascular Sealant Shown to be Safe and Effective for Vascular Reconstruction
-
Gecko Biomedical Rebrands as TISSIUM
5/14/2019
TISSIUM branding reflects broader focus on tissue reconstruction
-
Tilak Announces CE Marking for Odysight, Its First Mobile Medical Game in Ophthalmology
6/14/2018
Tilak announced that Odysight, its first mobile medical game dedicated to the monitoring of patients with chronic eye diseases, has achieved CE marking.
-
Gecko Biomedical Secures €6 Million in Funding under the Investments for the Future Programme (Programme d’investissements d’avenir, PIA), to Industrialize and Develop Innovative Solutions for Tissue Reconstruction
1/24/2018
This funding is a contribution towards the industrialization and development of innovative solutions in the area of tissue reconstruction, and the peripheral nerve in particular.
-
Gecko Biomedical Builds Out Strategy For ‘Print On’ Polymers Platform
12/7/2017
Gecko’s proprietary technology platform is composed of fully synthetic light-activated polymers that can be ‘printed’ on living tissue inside and outside the body.